DK1295611T3 - Oligonukleotid-transformerende forbindelser - Google Patents

Oligonukleotid-transformerende forbindelser

Info

Publication number: DK1295611T3
Authority: DK; Denmark
Prior art keywords: oligonucleotide; transforming compounds; transforming; compounds; collagen
Prior art date: 2000-06-20

Application number

DK01938732.3T

Other languages

English (en)

Inventor

Shunichiro Kubota

Takahiro Ochiya

Hiroshi Itoh

Masayasu Furuse

Shunji Nagahara

Masaaki Terada

Akihiko Sano

Original Assignee

Dainippon Sumitomo Pharma Co

Koken Kk

Nat Cancer Ct

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-20

Filing date

2001-06-19

Publication date

2010-10-04

2001-06-19 Application filed by Dainippon Sumitomo Pharma Co, Koken Kk, Nat Cancer Ct filed Critical Dainippon Sumitomo Pharma Co

2010-10-04 Application granted granted Critical

2010-10-04 Publication of DK1295611T3 publication Critical patent/DK1295611T3/da

Links

108091034117 Oligonucleotide Proteins 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 title 1
230000001131 transforming effect Effects 0.000 title 1
102000008186 Collagen Human genes 0.000 abstract 1
108010035532 Collagen Proteins 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
210000004102 animal cell Anatomy 0.000 abstract 1
230000000692 anti-sense effect Effects 0.000 abstract 1
229920001436 collagen Polymers 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Inorganic Chemistry (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)

DK01938732.3T 2000-06-20 2001-06-19 Oligonukleotid-transformerende forbindelser DK1295611T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2000184502		2000-06-20
PCT/JP2001/005195 WO2001097857A1 (fr)	2000-06-20	2001-06-19	Preparations destinees au transfert d'oligonucleotides

Publications (1)

Publication Number	Publication Date
DK1295611T3 true DK1295611T3 (da)	2010-10-04

Family

ID=18684937

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01938732.3T DK1295611T3 (da)	2000-06-20	2001-06-19	Oligonukleotid-transformerende forbindelser

Country Status (10)

Country	Link
US (3)	US20040052840A1 (da)
EP (1)	EP1295611B1 (da)
JP (1)	JP5118285B2 (da)
AT (1)	ATE478688T1 (da)
AU (1)	AU2001264317A1 (da)
DE (1)	DE60142899D1 (da)
DK (1)	DK1295611T3 (da)
ES (1)	ES2349137T3 (da)
PT (1)	PT1295611E (da)
WO (1)	WO2001097857A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW586934B (en) *	1997-05-19	2004-05-11	Sumitomo Pharma	Immunopotentiating composition
US20040052840A1 (en) *	2000-06-20	2004-03-18	Shunichiro Kubota	Preparations for oligonucleotide transfer
KR100888566B1 (ko) *	2001-06-20	2009-03-12	다이닛본 스미토모 세이야꾸 가부시끼가이샤	핵산 도입을 촉진시키는 방법
US20100104631A1 (en) *	2001-08-13	2010-04-29	Lipella Pharmaceuticals Inc.	Method of treatment for bladder dysfunction
AU2003264507A1 (en) *	2002-09-20	2004-04-08	Koken Co., Ltd.	Site-specific gene conversion promoter and gene therapeutic
JP4954550B2 (ja) *	2003-12-19	2012-06-20	大日本住友製薬株式会社	新規な核酸導入法
US20090062184A1 (en) *	2005-03-24	2009-03-05	Dainippon Sumitomo Pharma Co., Ltd.	Fine particulate preparation comprising complex of nucleic acid molecule and collagen
US7838502B2 (en) *	2005-05-06	2010-11-23	University Of Massachusetts Medical School	Compositions and methods to modulate H. influenzae pathogenesis
WO2006126600A1 (ja) *	2005-05-25	2006-11-30	National University Corporation Nagoya Universtiy	血管閉塞性疾患用医薬組成物
KR100777249B1 (ko)	2006-02-14	2007-11-28	(주)바이오니아	건조 올리고뉴클레오티드 조성물 및 이의 제조 방법
WO2010078403A2 (en) *	2008-12-30	2010-07-08	Lipella Pharmaceuticals Inc.	Methods and compositions for diagnosing urological disorders
FR3066115B1 (fr)	2017-05-10	2019-06-28	Universite de Bordeaux	Comprimes de vecteurs d'acides nucleiques

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5115094B2 (da) *	1972-11-01	1976-05-14
US5069936A (en) *	1987-06-25	1991-12-03	Yen Richard C K	Manufacturing protein microspheres
US5078997A (en) *	1988-07-13	1992-01-07	Cetus Corporation	Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5098890A (en) *	1988-11-07	1992-03-24	Temple University-Of The Commonwealth System Of Higher Education	Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5936035A (en) *	1988-11-21	1999-08-10	Cohesion Technologies, Inc.	Biocompatible adhesive compositions
US5614587A (en) *	1988-11-21	1997-03-25	Collagen Corporation	Collagen-based bioadhesive compositions
JP3187410B2 (ja) *	1989-08-10	2001-07-11	住友製薬株式会社	脳内投与用徐放性製剤
US5542935A (en) *	1989-12-22	1996-08-06	Imarx Pharmaceutical Corp.	Therapeutic delivery systems related applications
US5264618A (en) *	1990-04-19	1993-11-23	Vical, Inc.	Cationic lipids for intracellular delivery of biologically active molecules
FR2694895B1 (fr) *	1992-08-20	1994-11-10	Coletica	Procédé de fabrication de microparticules en émulsion par modification de la composition chimique de la phase dispersée après émulsification.
US5646042A (en) *	1992-08-26	1997-07-08	Ribozyme Pharmaceuticals, Inc.	C-myb targeted ribozymes
NZ267291A (en) *	1993-05-28	1997-09-22	Chiron Corp	Peptide inhibitors of urokinase receptor activity
DK0717617T3 (da) *	1993-09-09	2001-02-05	Schering Ag	Mikropartikler indeholdende aktive bestanddele og gas
CA2140053C (en) *	1994-02-09	2000-04-04	Joel S. Rosenblatt	Collagen-based injectable drug delivery system and its use
US5942496A (en) *	1994-02-18	1999-08-24	The Regent Of The University Of Michigan	Methods and compositions for multiple gene transfer into bone cells
US5583034A (en) *	1994-02-22	1996-12-10	La Jolla Institute For Allergy And Immunology	Enhancement of adoptosis using antisense oligonucleotides
US5844107A (en) *	1994-03-23	1998-12-01	Case Western Reserve University	Compacted nucleic acids and their delivery to cells
US5563255A (en) *	1994-05-31	1996-10-08	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of raf gene expression
EP0769063A1 (en) *	1994-06-27	1997-04-23	The Johns Hopkins University	Targeted gene delivery system
US6998268B2 (en) *	1995-07-03	2006-02-14	Dainippon Sumitomo Pharma Co. Ltd.	Gene preparations
CN1230205C (zh) *	1995-07-03	2005-12-07	株式会社高研	基因制剂
JP3867160B2 (ja) *	1995-07-03	2007-01-10	大日本住友製薬株式会社	遺伝子製剤
CN1209068A (zh) *	1995-10-23	1999-02-24	海欧制药澳大利亚有限公司	作为基因治疗所用的dna载体的透明质酸及治疗异常视网膜血管化的vegf反义dna
PT1704878E (pt) *	1995-12-18	2013-07-17	Angiodevice Internat Gmbh	Composições de polímeros reticulados e métodos para a sua utilização
AU728146B2 (en) *	1996-03-14	2001-01-04	Immune Response Corporation, The	Targeted delivery of genes encoding interferon
US6133437A (en) *	1997-02-13	2000-10-17	Apoptogen, Inc.	Modulation of IAPs for the treatment of proliferative diseases
US5874006A (en) *	1996-10-31	1999-02-23	Matrix Pharmaceutical, Inc.	Aseptic collagen concentration process
US6042820A (en) *	1996-12-20	2000-03-28	Connaught Laboratories Limited	Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
US6218112B1 (en) *	1996-12-23	2001-04-17	Cobra Therapeutics Limited	Optimization of gene delivery and gene delivery system
JP2001509828A (ja) *	1997-01-08	2001-07-24	プロリゴ・エルエルシー	高分子のバイオコンジュゲーション
US6524613B1 (en) *	1997-04-30	2003-02-25	Regents Of The University Of Minnesota	Hepatocellular chimeraplasty
WO1999040771A2 (en) *	1998-02-13	1999-08-19	Selective Genetics, Inc.	Concurrent flow mixing for preparing compositions comprising gene therapy vectors
JP4424850B2 (ja) *	1998-05-22	2010-03-03	大日本住友製薬株式会社	安定な遺伝子製剤
EP2363133A1 (en) *	2000-03-31	2011-09-07	Trustees of Boston University	Composition comprising DNA fragments and medical and cosmetic uses thereof
US20040052840A1 (en) *	2000-06-20	2004-03-18	Shunichiro Kubota	Preparations for oligonucleotide transfer
JP2002325572A (ja) *	2000-12-25	2002-11-12	Univ Osaka	外来物質の導入方法
KR100888566B1 (ko) *	2001-06-20	2009-03-12	다이닛본 스미토모 세이야꾸 가부시끼가이샤	핵산 도입을 촉진시키는 방법
US7148342B2 (en) *	2002-07-24	2006-12-12	The Trustees Of The University Of Pennyslvania	Compositions and methods for sirna inhibition of angiogenesis
US20060030534A1 (en) *	2002-09-04	2006-02-09	Gabriele Dorn	Treatment of neurological disorders by dsrna administration
AU2003264507A1 (en) *	2002-09-20	2004-04-08	Koken Co., Ltd.	Site-specific gene conversion promoter and gene therapeutic
AU2003291678B2 (en) *	2002-11-01	2009-01-15	The Trustees Of The University Of Pennsylvania	Compositions and methods for siRNA inhibition of HIF-1 alpha
ATE477337T1 (de) *	2003-01-16	2010-08-15	Univ Pennsylvania	Zusammensetzungen und verfahren zur sirna-hemmung von icam-1
US8227434B1 (en) *	2003-11-04	2012-07-24	H. Lee Moffitt Cancer Center & Research Institute, Inc.	Materials and methods for treating oncological disorders
EP2784090A1 (en) *	2004-02-26	2014-10-01	Baylor Research Institute	Compositions for the treatment of systemic onset juvenile idiopathic arthritis
DK1799269T3 (da) *	2004-09-28	2016-10-03	Quark Pharmaceuticals Inc	Oligoribonukleotider og fremgangsmåder til anvendelse deraf til behandling af alopeci, akut nyresvigt og andre sygdomme
EP1802350A4 (en) *	2004-10-22	2009-02-18	Univ Laval	MODULATION OF BDNF FROM NEUROGLIA IN THE TREATMENT AND PREVENTION OF PAIN
US7585848B2 (en) *	2005-01-11	2009-09-08	Rush University Medical Center	Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
EP1983823A1 (en) *	2006-01-17	2008-10-29	VIB vzw	Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
EP2047864B1 (en) *	2006-06-16	2017-04-05	Taisho Pharmaceutical Co., Ltd.	Use of rpn2 gene expression inhibitor
RU2553561C2 (ru) *	2006-07-21	2015-06-20	Сайленс Терапьютикс Аг	Средства ингибирования экспрессии протеинкиназы 3
US7825101B2 (en) *	2006-08-30	2010-11-02	The Board Of Trustees Of The University Of Illinois	Modulation of MLCK-L expression and uses thereof
WO2008041933A2 (en) *	2006-10-02	2008-04-10	Aprea Ab	Rna interference against wrap53 to treat hyperproliferative diseases
US7812002B2 (en) *	2007-03-21	2010-10-12	Quark Pharmaceuticals, Inc.	Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
JP2013512677A (ja) *	2009-12-04	2013-04-18	オプコオプサルミクス、エルエルシー	Ｖｅｇｆの阻害のための組成物および方法

2001
- 2001-06-19 US US10/311,621 patent/US20040052840A1/en not_active Abandoned
- 2001-06-19 DE DE60142899T patent/DE60142899D1/de not_active Expired - Lifetime
- 2001-06-19 AU AU2001264317A patent/AU2001264317A1/en not_active Abandoned
- 2001-06-19 PT PT01938732T patent/PT1295611E/pt unknown
- 2001-06-19 JP JP2002503340A patent/JP5118285B2/ja not_active Expired - Fee Related
- 2001-06-19 WO PCT/JP2001/005195 patent/WO2001097857A1/ja active Application Filing
- 2001-06-19 ES ES01938732T patent/ES2349137T3/es not_active Expired - Lifetime
- 2001-06-19 AT AT01938732T patent/ATE478688T1/de active
- 2001-06-19 EP EP01938732A patent/EP1295611B1/en not_active Expired - Lifetime
- 2001-06-19 DK DK01938732.3T patent/DK1295611T3/da active
2009
- 2009-06-17 US US12/486,703 patent/US20090258933A1/en not_active Abandoned
2010
- 2010-10-13 US US12/904,054 patent/US20110028535A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20090258933A1 (en)	2009-10-15
JP5118285B2 (ja)	2013-01-16
ES2349137T3 (es)	2010-12-28
EP1295611A1 (en)	2003-03-26
DE60142899D1 (de)	2010-10-07
US20040052840A1 (en)	2004-03-18
AU2001264317A1 (en)	2002-01-02
EP1295611B1 (en)	2010-08-25
ATE478688T1 (de)	2010-09-15
EP1295611A4 (en)	2009-07-08
WO2001097857A1 (fr)	2001-12-27
PT1295611E (pt)	2010-09-14
US20110028535A1 (en)	2011-02-03

Publication	Publication Date	Title
PT1459751E (pt)	2005-11-30	(s,s)-reboxetina para tratar as enxaquecas
WO2002036743A3 (en)	2003-01-16	Antisense modulation of calreticulin expression
ATE263354T1 (de)	2004-04-15	Vorrichtung zur herstellung von kontaktkörpern
EP1569695A4 (en)	2006-12-06	ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
AU2001290706A1 (en)	2002-03-26	Antisense modulation of clusterin expression
MXPA03009645A (es)	2004-01-29	Proceso para preparar oxazolidinonas.
MXPA03003632A (es)	2003-09-10	Metodo para tratamiento de tumores usando terapia de combinacion.
DK1295611T3 (da)	2010-10-04	Oligonukleotid-transformerende forbindelser
WO2001029175A3 (en)	2001-10-11	Antisense modulation of fra-1 expression
WO2003053341A3 (en)	2005-05-26	Antisense modulation of ship-1 expression
WO2002095053A3 (en)	2003-05-01	Antisense modulation of src-c expression
AU2180501A (en)	2001-06-12	Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide
WO2004010956A3 (en)	2004-07-01	Antisense modulation of lar expression
WO2003052062A3 (en)	2005-03-10	Antisense modulation of cd36l1 expression
EP1642884A4 (en)	2007-12-26	PROCESS FOR PREPARING OPTICALLY ACTIVE 1-ALKYL SUBSTITUTED 2,2,2-TRIFLUORETHYLAMINE
WO2003027229A3 (en)	2004-03-11	Antisense modulation of rip2 expression
ES1044983Y (es)	2000-12-16	Aparato de termoestimulacion para tratamientos terapeuticos.
WO2003044167A3 (en)	2004-02-12	Antisense modulation of human fxr expression
WO2002041836A3 (en)	2002-08-29	Antisense modulation of src-1 expression
WO2004001061A3 (en)	2006-02-23	Antisense modulation of heme oxygenase 1 expression
WO2003033659A3 (en)	2004-03-25	Antisense modulation of matrix metalloproteinase 1 expression
ES1045858Y (es)	2001-04-01	Maquina para tratamiento de aceitunas.
WO2003031576A3 (en)	2003-09-12	Antisense modulation of inhibitor-kappa b kinase-gamma expression
WO2002055535A3 (en)	2002-10-31	Antisense modulation of cytohesin-1 expression
WO2004015126A3 (en)	2004-07-01	Antisense modulation of edg1 expression